Recent advances in gut microbiota-mediated regulation of fat deposition and metabolic disorders. [PDF]
Cui X, Yuan Q, Long J, Zhou J.
europepmc +1 more source
ABSTRACT The potential adverse effects of 17‐alpha‐ethynylestradiol (50, 100, and 500 μg EE2/kg b.w., for 30 days) on tench (Tinca tinca) were evaluated by integrating biomarkers including physiological (hepato‐somatic index, spleen‐somatic index, and hematocrit), oxidative stress (catalase, glutathione peroxidase, and glutathione reductase activities;
Ana L. Oropesa +3 more
wiley +1 more source
Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]
Izarraras K +5 more
europepmc +1 more source
SLC35C2 promotes stemness and progression in hepatocellular carcinoma by activating lipogenesis
Chunhui Qi +7 more
openalex +1 more source
Metabolic Control and Regulation of Lipogenesis in the Mammalia
Yasutoshi Muto
openalex +2 more sources
Early nocturnal meal skipping alters the peripheral clock and increases lipogenesis in mice [PDF]
Chika Yoshida +4 more
openalex +1 more source
Physiological Differences in Sebum Composition in Regularly Menstruating Healthy Women
ABSTRACT Sex hormones regulating the menstrual cycle influence sebaceous gland cell lipogenesis and the feeling of skin oiliness or dryness on the face. The aim of this study was to elucidate sebaceous lipogenesis in females during the menstrual cycle and define their facial sebum composition.
Hiu Fung Lau +11 more
wiley +1 more source
Dietary fibre-adapted gut microbiome clears dietary fructose and reverses hepatic steatosis. [PDF]
Jung S +19 more
europepmc +1 more source
Consumption of resistant starch decreases postprandial lipogenesis in white adipose tissue of the rat [PDF]
Janine Higgins +2 more
openalex +1 more source
Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction–Associated Steatotic Liver Disease
Statins reduce low‐density lipoprotein‐cholesterol (LDL‐C) production and reduce cardiovascular risk and hepatic steatosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), but they have no significant effect on steatohepatitis and/or fibrosis.
Eleni Theocharidou, Thomas Gossios
wiley +1 more source

